Ascelia Pharma says FDA may accept SPARKLE reanalysis

Ascelia says it received FDA Type A minutes for Orviglance and that the FDA may accept a prospective SPARKLE image reanalysis with a different primary endpoint, while requiring added clinical evidence. The company says it will not run a new study and will pursue EU regulatory and partnering paths.